Table 1.
Study participants.
| Hydroxychloroquine | Ivermectin | Povidone-iodine | Zinc & vitamin C | Vitamin C | |
|---|---|---|---|---|---|
| N = 432 | N = 617 | N = 735 | N = 634 | N = 619 | |
| Participant characteristics | |||||
| Age (y), mean (SD) | 30.6 (6.4) | 33.6 (6.9) | 32.0 (6.6) | 33.2 (7.8) | 32.9 (7.1) |
| Country of origin | |||||
| Bangladesh | 166 (38.4%) | 324 (52.5%) | 259 (35.2%) | 305 (48.1%) | 288 (46.5%) |
| India | 265 (61.3%) | 256 (41.5%) | 474 (64.5%) | 327 (51.6%) | 320 (51.7%) |
| Others | 1 (0.2%) | 37 (6.0%) | 2 (0.3%) | 2 (0.3%) | 11 (1.7%) |
| No room exposurea | 293 (67.8%) | 378 (61.3%) | 482 (65.6%) | 457 (72.1%) | 399 (64.5%) |
| Medical history | |||||
| Hypertension | 2 (0.5%) | 8 (1.3%) | 3 (0.4%) | 12 (1.9%) | 3 (0.5%) |
| Diabetes mellitus | 1 (0.2%) | 2 (0.3%) | 3 (0.4%) | 2 (0.3%) | 2 (0.3%) |
| Hyperlipidemia | 0 | 3 (0.5%) | 0 | 1 (0.2%) | 0 |
| Baseline parameters | |||||
| Systolic BP (mmHg) | 123.8 (11.3) | 132.8 (15.1) | 130.2 (15.0) | 130.1 (16.6) | 128.4 (16.1) |
| Diastolic BP (mmHg) | 79.2 (6.9) | 86.7 (10.0) | 84.8 (10.7) | 86.3 (11.0) | 84.5 (10.7) |
| Pulse rate (per min)b | 86.5 (9.3) | 92.6 (12.2) | 92.9 (13.5) | 89.9 (13.7) | 90.9 (12.9) |
| Body mass index (kg/m2) | 23.2 (3.2) | 25.2 (2.7) | 23.8 (3.5) | 24.2 (3.5) | 24.0 (3.2) |
Age and country of origin were verified with their employment identification documents; other countries of origin included China, Malaysia, Myanmar, the Philippines and Thailand.
a
Denotes number (%) of participants living in rooms that never had anyone diagnosed with COVID-19 at the time of randomization.
b
Denotes resting heart rate.